Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Pioglitazone and metformin.

Nathan R Hill¹, David R Matthews

¹Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK.

Drugs of Today (Barcelona, Spain : 1998)

|August 31, 2007

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Leveraging generative artificial intelligence for the development of non-interventional research study protocols: a proof-of-concept feasibility study.

BMC medical research methodology·2026

Same author

Impact of social determinants of health on treatment patterns and outcomes in metastatic non-small cell lung cancer.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Same author

Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study.

BMJ open respiratory research·2025

Same author

Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical Data.

JCO oncology practice·2025

Same author

Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetes.

Diabetes, obesity & metabolism·2024

Same author

The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program.

The Lancet. Rheumatology·2024

Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023

See all related articles

The combination of pioglitazone and metformin for type 2 diabetes is safe and effective. Side effects are predictable and not increased when using this combination therapy.

Area of Science:

Endocrinology
Pharmacology
Diabetes Management

Background:

Pioglitazone and metformin are established treatments for type 2 diabetes.
Combining these agents into a single tablet offers potential therapeutic advantages.

Purpose of the Study:

To review available data on the efficacy and safety of pioglitazone and metformin combination therapy.
To assess the therapeutic benefits and side effect profile of this combined treatment.

Main Methods:

Review of existing clinical trial data.
Analysis of studies involving concurrent administration of pioglitazone and metformin.
Examination of data from monotherapy with each agent.

Main Results:

Related Experiment Videos

The combination of pioglitazone and metformin demonstrates therapeutic efficacy in type 2 diabetes.

The combined treatment is clinically safe, with no additive side effects.

Adverse events are consistent with those expected from individual agent monotherapy.

Conclusions:

Pioglitazone and metformin combination therapy is a safe and effective treatment option for type 2 diabetes.
The combination offers a logical approach to managing type 2 diabetes, with a predictable side effect profile.